Results 171 to 180 of about 2,471,157 (341)
Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism
Molecular Oncology, EarlyView.Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch +16 morewiley +1 more sourceProspective observational cohort study of the association between antiplatelet therapy, bleeding and thrombosis in patients with coronary stents undergoing noncardiac surgery
, 2018 Simon Howell, Sanne E. Hoeks, Robert West, Stephen G. Wheatcroft, Andreas Hoeft, B. Leva, B. Plichon, Sabrine Damster, Mona Momeni, Christine Watremez, D. Kahn, Anne-Sophie Dincq, Aida Danila, Mária Wittmann, Rafael Struck, T. Rüddel, F. J. Kessler, Stefan Rasche, Paraskevi Matsota, Antigona Hasani, Jūratė Gudaitytė, Aurika Karbonskienė, Rafael Meneguzzi Alves Ferreira, Susana Carvalho, Dana Tomescu, C. Martac, Ioana Marina Grințescu, Lucia Mirea, Leyre Serrano Fernández, Leyre Serrano Fernández, P. Sierra, Sergi Sabaté, David Hernando, P. Matute, M. Trashorras, M. Suñé, L Argüello, Adriana Hervías, Óscar González‐Lorenzo, Andrew Hermina, Óscar González‐Lorenzo, Andrew Hermina, R. Perez, María Isabel Orts, Raquel Fernández-García, D. Sánchez Pérez, I. Sepulveda Gil, Pablo Monedero, Francisco Hidalgo, C. Mbongo, A. Rodríguez, Hugo Reyes, Carlos Bártolo, S López Galera, Tabita M. Valentijn, Robert Jan Stolker, Mehmet Tuğrul, Ebru-Berrin Demirel, M. Hough, K. Griffiths, Stephen Birch, Z. Beardow, S. Elliot, Jonathan P. Thompson, Sarah Bowrey, Martin Northey, H. Melson, Richard J. Telford, Maria Nadolski, A. Potter, Daniela T. Fuller, Adam J. Rose, S. Varma, Karen Simeson, Joshua Pettit, Nicola Jayne Smith, Victoria Martinson, Lisa Sleight, C. David Naylor, P. R. Watt, Parizade Raymode, Nigel Dunk, Linda Twohey, Laszlo Hollos, Simon Davies, Andrew K. Gibson, Zoe Coleman, Tamm Ti, J. Joscak, Lajos Zsisku, M. Zuleika, P. Carvalho, T. Collyer, Jason Ryan, Kristin P. Colling, S. Dharmarajah, Anand Muthu Krishnan, Jonathan Paddle, Anna Fouracres, Kai Arnell +99 moreopenalex +1 more sourcePatient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
Molecular Oncology, EarlyView.This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert +16 morewiley +1 more sourcePredictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman +17 morewiley +1 more sourceTreatment Strategies in Ebstein's Anomaly: An Observational Study Over Three Decades. [PDF]
Interdiscip Cardiovasc Thorac SurgMurin P, Lorenzen V, Romanchenko O, Winter M, Weixler V, Ovroutski S, Cho MY, Kühne T, Berger F, Photiadis J, Kelm M. +10 moreeuropepmc +1 more sourceAggressive prostate cancer is associated with pericyte dysfunction
Molecular Oncology, EarlyView.Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera +11 morewiley +1 more source
